CJC-1295

The most informative human work on CJC-1295 examined what happens to natural GH rhythms when the pituitary is stimulated continuously. A clinical trial in healthy men aged 20–40 measured GH levels every 20 minutes across a 12-hour overnight window, both before and one week after a single injection of CJC-1295 at either 60 or 90 µg/kg (1).

The results were striking. Trough (baseline) GH levels rose roughly 7.5-fold, and overall mean GH levels increased by about 46%. IGF-1, the downstream growth factor that mediates many of GH's effects on tissue, climbed approximately 45%. Importantly, the natural pulsatile pattern of GH release — the rhythmic peaks that occur throughout the day and especially during sleep — was preserved. The frequency and magnitude of GH pulses didn't change; what changed was the floor between pulses, which lifted substantially (1).

This matters because pulsatility is thought to be important for many of GH's physiological effects, and a concern with any long-acting GH-releasing compound is that it might flatten those pulses into a continuous plateau. CJC-1295 appears to raise the baseline without disrupting the rhythm, which may explain why a single weekly injection can produce sustained IGF-1 elevation without obviously dysregulating the system.

What sets CJC-1295 apart from earlier GHRH analogs is the maleimide group on its C-terminus. Maleimide reacts spontaneously with free thiol groups (sulfur-containing side chains) on cysteine residues, and serum albumin carries an accessible cysteine that acts as the primary binding partner once CJC-1295 enters the bloodstream (2, 3).

This covalent attachment effectively converts a small, rapidly cleared peptide into a macromolecule the size of a serum protein. The conjugate continues to stimulate GH production for more than six days after a single dose in humans, compared to minutes for unmodified GHRH (2). It also makes the peptide remarkably difficult to detect by standard mass-spectrometry methods used in anti-doping screening, because the conjugated form has no defined molecular weight — it's bound to whatever albumin or other thiol-bearing protein it encountered first (2, 3).

Researchers have developed specialized assays to address this, including immuno-PCR screens capable of detecting the conjugate at concentrations as low as 0.8 pg/mL and LC-MS/MS confirmation methods after enzymatic digestion of the carrier protein (2, 3). The analytical difficulty itself is a consequence of how well the albumin-binding strategy works pharmacologically.

Outside of formal clinical trials, CJC-1295 has circulated widely in performance and physique-enhancement communities. A 2010 forensic analysis confirmed its presence in unmarked pharmaceutical preparations seized by Norwegian customs authorities, sequencing the 29-amino-acid peptide with C-terminal amide directly from the unknown product (4).

A qualitative analysis of bodybuilding forums examined how it's actually being used, focusing on female users across nine forum communities (5). The reported motivations clustered around fat loss, muscle enhancement, improved skin appearance, better sleep quality, and injury recovery — a profile consistent with elevated GH and IGF-1 activity. Users in these communities discussed dosing strategies and cycling protocols in considerable detail, including concerns about how continuous GHRH stimulation might interact with female-specific GH pulse patterns (5).

This self-reported usage data isn't a substitute for controlled research, but it does describe the effects users consistently associate with the peptide and the practical considerations they navigate when deciding how to administer it.

Reported side effects in the available clinical research are limited. The human pharmacokinetic study found no significant adverse events at doses of 60 or 90 µg/kg, and IGF-1 elevations remained within physiological ranges (1). User-reported effects in community discussions include water retention, occasional tingling or numbness, mild injection-site reactions, and in some cases increased hunger or fatigue early in use (5). Long-term safety data in humans is limited because large-scale trials have not been completed.

The body of CJC-1295 evidence comes primarily from preclinical and laboratory work, with a small number of human pharmacokinetic studies and limited broader clinical data so far.

CJC-1295 is classified as a Prohibited Substance under Section S2 of the World Anti-Doping Agency list, and detection assays for both human and equine sport have been developed and deployed (2, 3, 4) — relevant context for anyone subject to athletic testing.